Pioglitazone

Hmm… We’d better think about this again. Pioglitazone is not a good first‑line choice because it causes weight gain and fluid retention and it lacks clear cardiovascular outcome benefits. If a thiazolidinedione is considered at all, it is considered in cases where first line drugs are not indicated or unavailable, or in combination with other first line drugs.

Try to think about other drugs with favourable weight and cardiovascular profiles. Always consider the full clinical context when prescribing medications and try again!

  • Presentation
End Session and View Feedback
  • Insulin [undo]
  • Methimazole [undo]
  • Empagliflozin [undo]
  • Metformin [undo]
  • Pioglitazone [undo]
  • Game Over [undo]
  • Presentation [undo]
  • Game Over [undo]
  • Scientific evidence is important [undo]
  • Presentation [undo]
  • Game Over [undo]
  • PICO [undo]
  • Game Over [undo]
  • Game Over [undo]
  • Insulin [undo]
  • Empagliflozin [undo]
  • Pioglitazone [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21115
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • CELL STRUCTURE AND FUNCTION
  • Insulin
  • Methimazole
  • Empagliflozin
  • Metformin
  • Pioglitazone
  • Game Over
  • Presentation
  • Game Over
  • Scientific evidence is important
  • Presentation
  • Game Over
  • PICO
  • Game Over
  • Game Over
  • Insulin
  • Empagliflozin
  • Pioglitazone

Reminder

empty_reminder_msg

FINISH

Time is up